Eleva Appoints Donato Spota as Chief Financial Officer
Freiburg im Breisgau, Germany, May 13, 2025 – Eleva, a pioneer in discovering and developing previously inaccessible biologics based on a breakthrough technology platform, appointed Mr. Donato Spota as Chief Financial Officer (CFO) and Managing Director. Mr. Spota brings to Eleva profound expertise in complementary business areas including strategic finance, investor relations, business development and international capital markets transactions. Danielle Püschel, currently serving as CFO, is appointed as Chief Accounting Officer.
'Eleva continues to strengthen its leadership team in line with the growing maturity of our proprietary development activities and steady progress in commercializing our technology platform. It is a pleasure to welcome Donato, whose proven experience in financial management of rapidly growing companies, makes him the ideal candidate to help us successfully navigate the ongoing transformation of Eleva,' commented Björn Cochlovius, Ph.D., Chief Executive Officer and Managing Director of Eleva. 'I also want to express my special thanks to Danielle Püschel for her commitment and leadership over the last 16 years at Eleva. The entire team is glad Danielle will continue her career with the company.'
Mr. Spota is a senior executive with more than 25 years of international pharmaceutical industry experience. In his previous position as CFO of Hansa Biopharma, a Nasdaq Stockholm-listed biopharmaceutical company, he supported the progress of Hansa Biopharma's R&D pipeline and its transformation to a commercial-stage company by contributing to the corporate business and financial strategy and securing growth financing in excess of USD 200 million. Prior to joining Hansa Biopharma, Mr. Spota was CFO at Basilea Pharmaceutica AG, a Swiss-listed biopharmaceutical company. Mr. Spota held other senior financial leadership positions, including Global Head of Finance & Services and Head of Global Controlling at Basilea. Mr. Spota holds a degree in Information Technology and an M.Sc. in Business Administration from the HfWU University Nürtingen-Geislingen, Germany.
Donato Spota added: 'Eleva is accelerating and expanding both of its core business activities in proprietary drug development and high-value product partnerships based on our transformative technology platform. I'm looking forward to working closely with Björn and the leadership team to help refine and successfully execute Eleva's growth strategy for both strategic pillars of this exciting business.'
ABOUT ELEVA Eleva is a clinical-stage biopharmaceutical company discovering and developing previously inaccessible biologics based on a breakthrough moss-based technology platform. The company's proprietary pipeline includes candidates for complement disorders and enzyme replacement therapies. Factor H (CPV-104), a recombinant human complement Factor H, is expected to enter clinical studies in C3 Glomerulopathy (C3G) in H1 2025. Dry AMD has been selected as the second indication. The company's aGal (RPV-001) program to treat Fabry disease has completed a positive Phase 1b clinical trial. All programs are sourced from Eleva's transformative moss-based technology platform, which allows lab to GMP-scale manufacturing of previously undruggable human proteins with tremendous therapeutic potential.
MEDIA CONTACTS
Fabienne ZeitterDirector Marketingpr@elevabiologics.com Phone: +49 761 470 99 0
Valency CommunicationsMario Brkuljmbrkulj@valencycomms.euPhone: +49 160 9352 9951
INVESTOR CONTACT
Cohesion BureauGiovanni Ca' Zorzigiovanni.cazorzi@cohesionbureau.com Phone: +33 7 84 67 07 27
Attachments
13MAY2025_Eleva_CFO_Appointment_ENG_FINAL
Donato Spota
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
ASML Stock Falls on CEO's Warning: 2026 May Be a Flat Year
July 16 ASML (NASDAQ:ASML), the world's leading supplier of chip?making equipment, warned it may not deliver revenue growth in 2026, sending its shares sliding about 7% in early Wednesday trading. The company reported second?quarter net bookings of 5.54 billion, topping analysts' average forecast of 4.44 billion from Visible Alpha. The strong order intake was driven largely by artificial intelligence?related demand. Chief Executive Christophe Fouquet said the level of uncertainty is increasing, mostly due to macroeconomic and geopolitical considerations, including tariffs. Chief Financial Officer Roger Dassen added that ASML is working closely with its supply chain to mitigate potential impacts. While we still prepare for growth in 2026, we cannot confirm it at this stage, Fouquet said, noting that a flat year would break a decade of uninterrupted revenue gains since 2012. Aureus Investment's CIO Han Dieperink said he remains not overly concerned, citing the quarter's solid bookings as a sign of resilient customer demand. ASML's extreme?ultraviolet lithography systems underpin advanced chips used in Nvidia (NASDAQ:NVDA) GPUs and Apple (NASDAQ:AAPL) devices. Chinese machine sales held steady at 27% of total volumes over the past three quarters, above earlier estimates of 20%, suggesting chipmakers there are still sourcing equipment ahead of tighter export controls. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17 minutes ago
- Yahoo
DMN Group unveils two senior hires
DMN Group, a provider of vehicle movement and fleet inspection services, has announced two senior leadership appointments following a period of growth for the business, according to a press release. Gary Xuereb has been named managing director of DMN Fleet Services. In this role, he will oversee day-to-day operations for what the company describes as a "rapidly expanding division." Xuereb previously held the position of group commercial director. Replacing Xuereb, Maria McDonald (formerly Avery) has been promoted to group commercial director. She steps up from her role as account director at DMN Rapid Logistics and will now lead the group's commercial strategy. The company says she brings with her 'customer-centric elements' from her previous post, positioning her to drive strategic growth across the business. These changes come as DMN Group continues to benefit from recent acquisitions, including Specialist Vehicle Logistics (SVL) and JLL Vehicle Distribution. The integration of both companies has 'brought enhanced synergy' to DMN's operations. JLL Vehicle Distribution, in particular, has reported record-breaking results for vehicle movements and revenue in 2025, with growth in contracts, client base, and staffing. Meanwhile, SVL's smooth integration with DMN's IT systems has helped secure new clients and 'driven unexpected growth.' Demand continues to surge across DMN Fleet Services, especially for service, maintenance and repair (SMR), MOTs, and bodyshop services. The company has seen its workforce increase by a third, prompting the need for what it calls 'reinforced management, guidance, and support.' Commenting on the appointments, DMN Group's managing director Nick Chadaway said the business is 'thriving,' adding: 'It all comes down to our processes and our people.' He said both Xuereb and McDonald 'know the business, the sector, and the company inside-out' and are ideally placed to lead DMN into its next phase of growth. "DMN Group unveils two senior hires" was originally created and published by Motor Finance Online, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17 minutes ago
- Yahoo
Alvotech (ALVO) Announces Acquisition of Ivers-Lee Group
Alvotech (NASDAQ:ALVO) is one of the best oversold NASDAQ stocks to buy now. On July 9, Alvotech (NASDAQ:ALVO) announced that it is expanding its capacity for assembly and packaging by acquiring Ivers-Lee Group, a family-owned Swiss company that specializes in high-quality pharmaceutical assembly and packaging services. A scientist in a laboratory working on drug research. Although Ivers-Lee will continue existing as a separate legal entity, its operations will be integrated into Alvotech's (NASDAQ:ALVO) Technical Operations division. The acquisition would, therefore, support Alvotech's (NASDAQ:ALVO) ambitious growth plans, increasing its flexibility and capacity to meet the rising global demand for biosimilars. Robert Wessman, founder, chairman, and CEO of Alvotech (NASDAQ:ALVO), stated that the company is preparing for the launch of three new biosimilars in 2025, along with sales growth in global markets, and that the acquisition would support these plans. Alvotech (NASDAQ:ALVO) is a biotechnology company that develops and manufactures biosimilar medicines. Headquartered in Luxembourg, the company operates in the following geographical segments: Europe, North America, Asia, and Other. While we acknowledge the potential of ALVO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error al recuperar los datos Inicia sesión para acceder a tu cartera de valores Error al recuperar los datos Error al recuperar los datos Error al recuperar los datos Error al recuperar los datos
